75 mg PO BID x 5 days
Currently available data are insufficient to recommend a specific dose of oseltamivir for premature infants; it is strongly recommended that an Infectious Diseases physician or clinical pharmacist be consulted.
3 mg/kg/dose PO BID x 5 days
10 - 30 eGFR31 - 60 eGFR60+ eGFR30 mg PO daily x 5 days30 mg BID x 5 days75 mg PO BID x 5 days
Treatment and prophylaxis of influenza A and B.
Reports describing the use of oseltamivir during human pregnancy do not suggest a significant risk of developmental toxicity.
Influenza infection in pregnancy is a high-risk condition, the maternal benefit far outweighs the unknown risk, if any, to the embryo or fetus.
Oseltamivir and its active metabolite are poorly excreted into breastmilk.
Maternal dosages of 150 mg daily produce low levels in milk and would not be expected to cause any adverse effects in breastfed infants.
Therapeutic doses of oseltamivir are given to newborns with influenza.
GI upset common
Rare - Stevens Johnson Syndrome
Neuropsychiatric side effects reported
No significant drug interactions.
Will only treat Influenza A and B. Does NOT treat RSV, parainfluenza, human metapneumovirus, adenovirus, or other common viral pathogens. Discontinue if influenza test results return negative.
Note that pregnant and postpartum (up to 4 weeks) are considered high risk of complications from influenza and treatment is recommended in this population.
Greatest benefit is seen if treatment is started within 48 h of symptom onset, however, treatment may still be beneficial and should be started in high risk patients, and hospitalized patients with severe, complicated or progressive illness if > 48 hours.
Antimicrobial class: Antiviral - neuraminidase inhibitor.